24 results
Thumbnail

- D3.218 - The prevalence of sensitization to major food allergens among children with seasonal allergy symptoms, skin allergy and/or complaints of allergic reactions upon consuming certain food products

Thumbnail

D3.219 - Selective Octopus Allergy: A Unique Case Report

Thumbnail

D3.207 - Exercise-Induced Anaphylaxis: A Case Study on Pea Consumption and Allergenic Protein Profiling

Thumbnail

D3.208 - Alpha-L-Fucosidase and Other Allergens in Cardamom-Induced Allergy: A Case Study

Thumbnail

D3.209 - Cross-Reactivity Between Birch Pollen and Hazelnut: A Case Study on PR-10 Allergens

Thumbnail

D3.210 - Profiling Allergens in Saffron and Achiote: A Case Study on Spice-Induced Anaphylaxis

Thumbnail

D3.211 - Alpha-Actinin and Hemocyanin as Major Allergens in Crustacean Allergy: A Case Study

Thumbnail

D3.213 - Anaphylaxis to Sumac in a Patient with Cashew and Pistachio Allergy: Cross-Reactivity Among Anacardiaceae Species

Thumbnail

D3.214 - Flexible and Safe Oral Immunotherapy (OIT) Regimen Using Home Boiled Nut Broths (HBNB)

Thumbnail

D3.215 - An unusual cause of frequent episodes of severe nausea with near-fainting

Thumbnail

D3.216 - Audit of Peanut Allergy Patients Eligible for Oral Immunotherapy (OIT) in a Paediatric Cohort at Galway University Hospital (2020-2023)

Thumbnail

D3.217 - Lentils anaphylaxis: BAT to the rescue!

Thumbnail

D3.222 - Contact urticaria to raw potato possible due to cross-reactivity with birch pollen

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series